vs
利氏兄弟拍卖行（RBA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 9.1%，领先3.6%），Revvity同比增速更快（5.9% vs 5.4%），利氏兄弟拍卖行自由现金流更多（$186.5M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.3%）
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RBA vs RVTY — 直观对比
营收规模更大
RBA
是对方的1.6倍
$772.1M
营收增速更快
RVTY
高出0.4%
5.4%
净利率更高
RVTY
高出3.6%
9.1%
自由现金流更多
RBA
多$24.7M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $109.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 14.7% | 14.5% |
| 净利率 | 9.1% | 12.7% |
| 营收同比 | 5.4% | 5.9% |
| 净利润同比 | -7.4% | 3.9% |
| 每股收益（稀释后） | $0.53 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RBARVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $981.8M | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.1B | $649.9M |
净利润RBARVTY
| Q4 25 | $109.7M | $98.4M | ||
| Q3 25 | $95.5M | $46.7M | ||
| Q2 25 | $109.8M | $53.9M | ||
| Q1 25 | $113.4M | $42.2M | ||
| Q4 24 | $118.5M | $94.6M | ||
| Q3 24 | $76.1M | $94.4M | ||
| Q2 24 | $111.1M | $55.4M | ||
| Q1 24 | $107.4M | $26.0M |
毛利率RBARVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率RBARVTY
| Q4 25 | 14.7% | 14.5% | ||
| Q3 25 | 14.5% | 11.7% | ||
| Q2 25 | 15.9% | 12.6% | ||
| Q1 25 | 17.1% | 10.9% | ||
| Q4 24 | 18.1% | 16.3% | ||
| Q3 24 | 15.6% | 14.3% | ||
| Q2 24 | 18.4% | 12.4% | ||
| Q1 24 | 18.7% | 6.8% |
净利率RBARVTY
| Q4 25 | 9.1% | 12.7% | ||
| Q3 25 | 8.7% | 6.7% | ||
| Q2 25 | 9.3% | 7.5% | ||
| Q1 25 | 10.2% | 6.4% | ||
| Q4 24 | 10.4% | 13.0% | ||
| Q3 24 | 7.8% | 13.8% | ||
| Q2 24 | 10.1% | 8.0% | ||
| Q1 24 | 10.1% | 4.0% |
每股收益（稀释后）RBARVTY
| Q4 25 | $0.53 | $0.86 | ||
| Q3 25 | $0.43 | $0.40 | ||
| Q2 25 | $0.53 | $0.46 | ||
| Q1 25 | $0.55 | $0.35 | ||
| Q4 24 | $0.58 | $0.77 | ||
| Q3 24 | $0.36 | $0.77 | ||
| Q2 24 | $0.54 | $0.45 | ||
| Q1 24 | $0.53 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $531.5M | $919.9M |
| 总债务越低越好 | $2.3B | — |
| 股东权益账面价值 | $5.6B | $7.3B |
| 总资产 | $12.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.42× | — |
8季度趋势，按日历期对齐
现金及短期投资RBARVTY
| Q4 25 | $531.5M | $919.9M | ||
| Q3 25 | $674.7M | $931.4M | ||
| Q2 25 | $710.2M | $991.8M | ||
| Q1 25 | $578.1M | $1.1B | ||
| Q4 24 | $533.9M | $1.2B | ||
| Q3 24 | $650.7M | $1.2B | ||
| Q2 24 | $599.5M | $2.0B | ||
| Q1 24 | $462.8M | $1.7B |
总债务RBARVTY
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.9B | — |
股东权益RBARVTY
| Q4 25 | $5.6B | $7.3B | ||
| Q3 25 | $5.5B | $7.4B | ||
| Q2 25 | $5.5B | $7.6B | ||
| Q1 25 | $5.3B | $7.6B | ||
| Q4 24 | $5.2B | $7.7B | ||
| Q3 24 | $5.2B | $7.9B | ||
| Q2 24 | $5.2B | $7.9B | ||
| Q1 24 | $5.1B | $7.8B |
总资产RBARVTY
| Q4 25 | $12.1B | $12.2B | ||
| Q3 25 | $12.2B | $12.1B | ||
| Q2 25 | $12.2B | $12.4B | ||
| Q1 25 | $11.9B | $12.4B | ||
| Q4 24 | $11.8B | $12.4B | ||
| Q3 24 | $11.9B | $12.8B | ||
| Q2 24 | $12.1B | $13.4B | ||
| Q1 24 | $12.0B | $13.4B |
负债/权益比RBARVTY
| Q4 25 | 0.42× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.58× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $255.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $186.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.5% | 21.0% |
| 资本支出强度资本支出/营收 | 5.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.33× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $719.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RBARVTY
| Q4 25 | $255.2M | $182.0M | ||
| Q3 25 | $239.7M | $138.5M | ||
| Q2 25 | $326.5M | $134.3M | ||
| Q1 25 | $156.8M | $128.2M | ||
| Q4 24 | $184.5M | $174.2M | ||
| Q3 24 | $285.4M | $147.9M | ||
| Q2 24 | $337.3M | $158.6M | ||
| Q1 24 | $124.8M | $147.6M |
自由现金流RBARVTY
| Q4 25 | $186.5M | $161.8M | ||
| Q3 25 | $188.5M | $120.0M | ||
| Q2 25 | $241.7M | $115.5M | ||
| Q1 25 | $102.5M | $112.2M | ||
| Q4 24 | $127.9M | $149.8M | ||
| Q3 24 | $248.5M | $125.6M | ||
| Q2 24 | $308.6M | $136.6M | ||
| Q1 24 | $79.6M | $129.7M |
自由现金流率RBARVTY
| Q4 25 | 15.5% | 21.0% | ||
| Q3 25 | 17.3% | 17.2% | ||
| Q2 25 | 20.4% | 16.0% | ||
| Q1 25 | 9.2% | 16.9% | ||
| Q4 24 | 11.2% | 20.5% | ||
| Q3 24 | 25.3% | 18.4% | ||
| Q2 24 | 28.2% | 19.7% | ||
| Q1 24 | 7.5% | 20.0% |
资本支出强度RBARVTY
| Q4 25 | 5.7% | 2.6% | ||
| Q3 25 | 4.7% | 2.6% | ||
| Q2 25 | 7.2% | 2.6% | ||
| Q1 25 | 4.9% | 2.4% | ||
| Q4 24 | 5.0% | 3.4% | ||
| Q3 24 | 3.8% | 3.3% | ||
| Q2 24 | 2.6% | 3.2% | ||
| Q1 24 | 4.2% | 2.7% |
现金转化率RBARVTY
| Q4 25 | 2.33× | 1.85× | ||
| Q3 25 | 2.51× | 2.97× | ||
| Q2 25 | 2.97× | 2.49× | ||
| Q1 25 | 1.38× | 3.03× | ||
| Q4 24 | 1.56× | 1.84× | ||
| Q3 24 | 3.75× | 1.57× | ||
| Q2 24 | 3.04× | 2.87× | ||
| Q1 24 | 1.16× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
